The manufacturer of the interleukin-23 inhibitor tildrakizumab (Ilumya), Sun Pharma, announced today that the FDA has ...

People with psoriasis prescribed bimekizumab have no greater risk for major depressive disorder or suicidal ideation than ...

Sun Pharmaceutical Industries Limited. Sun Pharma announces US FDA acceptance of supplemental Biologics License Application for ILUMYA (tildrakizumab-asmn) for the treatment of adults with active ...

Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associated companies) announced that the US ...

If the sBLA is approved, expansion into psoriatic arthritis would build on the established clinical experience of ILUMYA as an IL-23 inhibitor for moderate-to-severe ...

Sun Pharmaceutical Industries Limited said on Monday, March 16, that the US Food and Drug Administration has accepted for review a supplemental Biologics License Application (sBLA) for ILUMYA.

Psoriasis is a chronic inflammatory disease that affects 1.3% of the Brazilian population. The most common clinical manifestations are erythematous, scaling lesions that affect both genders and can ...

In reality, nails are considered appendages of the skin, explains Chris Adigun, MD, a board-certified dermatologist and nail ...

A simulated analysis in psoriasis highlights divergent patient and payer incentives and inconsistent coverage strategies behind barriers to phototherapy uptake.

Homeopathic remedies help lock the moisture in the skin to prevent dryness, which calms the flare-ups. Moreover, it helps stimulate the body’s natural healing mechanisms, aiming to eliminate the root ...

Sotyktu (deucravacitinib) for treatment of adults with active psoriatic arthritis (PsA). Sotyktu is an oral, selective ...